. Multiple tumours surrounding the ulcer on the left lower leg at the time of the patient's first presentation (a). Dense infiltration of anaplastic large cells and lymphocytes in the dermis (H&E stain ×400) (b). Neoplastic cells were strongly positive for CD30. Immunohistochemical staining ×400 (c). Multiple tumours mostly disappeared 4 weeks after starting intralesional methotrexate (MTX) (d). The injection site 6 months after intralesional MTX therapy (e).
pear to be safe and effective treatments. However, surgical intervention may lead to marked defects with significant functional or cosmetic morbidity, depending on the size and location. In addition, old patients with comorbid conditions may be poor surgical candidates.
MTX is one of the effective treatments for CD30 + lymphoproliferative disorders (LPD). The mechanism presumably relates to its inhibitory effect on DNA synthesis, anti-inflammatory effects, or both. Bekkenk et al.
(1) recommended low-dose oral MTX for patients without spontaneous regression or multiple lesions. Vonderheid et al. (2) reported that compared with other treatments, MTX provided the highest response rate, exceeding 90% of all reported cases of CD30 + LPD. Blume et al. (3) reported that intralesional MTX therapy injected twice to the skin lesions of PCALCL at an interval of one week was successful. Intralesional MTX has also been used in the treatment of keratoacanthoma and the specific cutaneous involvement of B-cell chronic lymphocytic leukaemia (4) (5) (6) . In these circumstances, intralesional MTX may offer the advantage of being relatively noninvasive, less expensive, quickly administered, and requires fewer visits by the patient than radiotherapy or systemic chemotherapy. Although local pain at the injection site was observed as a side effect, premedication with local anesthesia was helpful in alleviating this pain. Intralesional MTX is particularly useful as a treatment in patients with PCALCL who are elderly and debilitated.
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